Market Signal Briefing

Nearly all participants (11 of 12) experienced clinically meaningful hearing improvements, including three who achieved normal hearing; eight with longer follow-up showed stability or continued improvement in their hearing

Among three who completed speech assessments, all showed significant improvement with one able to identify one- and two-syllable words with no visual cues and respond to distant sounds and speech in noisy environments

Latest DB-OTO data presented at AAO-HNSF; U.S. regulatory submission planned later this year, pending discussions with the FDA

TARRYTOWN, N.Y., Oct. 12, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced updated data for their investigational gene therapy DB-OTO for profound genetic hearing loss due to variants of the otoferlin (OTOF) gene were published in The New England Journal of Medicine and presented during an oral presentation at the annual American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNSF) meeting. These latest results from the pivotal CHORD trial show 11 out of 12 participants have experienced clinically meaningful hearing improvements, including 3 who achieved normal hearing levels. Additionally, eight participants with longer follow-up showed stability or continued improvement in their hearing, and among three who completed speech assessments, all showed significant improvement.

“Until now, genetic OTOF-related hearing loss was considered permanent, which is why many of us have dedicated our careers to this field,” said Lawrence R. Lustig, M.D., Chair of the Department of Otolaryngology-Head and Neck Surgery at the Columbia University College of Physicians and Surgeons and a trial investigator. “This registrational data set showcases consistent, rapid and robust responses to DB-OTO, and for those followed to later timepoints, we’ve seen hearing stability as well as continued improvement in understanding of speech. These results are even more poignant when viewed by the families – as one of the parents said, their situation is now ‘unimaginable’ from one year ago. This truly represents a new era in the treatment of hearing loss.”

The CHORD trial evaluated pediatric participants with profound hearing loss due to variants of the OTOF gene that received a single administration of DB-OTO via intracochlear infusion. Among 12 participants (aged 10 months to 16 years), nine received the gene therapy unilaterally (in one ear) and three received it bilaterally (in both ears). The surgical procedure to administer DB-OTO leverages an approach similar to cochlear implantation, which enables use in young infants.

Nearly all participants (11 of 12; 14 of 15 treated ears) demonstrated improved hearing, responding within weeks of treatment. As published and presented, the trial met the primary endpoint with 9 participants experiencing hearing improvements at a threshold of ≤70 decibel hearing level (dBHL) as assessed by behavioral pure tone audiometry (PTA) at week 24. This threshold corresponds to a clinical standard that typically does not require cochlear implantation and enables natural acoustic hearing. Notably, 6 could hear soft speech without assistive devices, and 3 were further able to detect whispers (achieving normal hearing sensitivity). One participant who did not meet the primary PTA endpoint at week 24 further improved to achieve “nearly normal” hearing sensitivity at week 48. Nine participants also demonstrated an auditory brainstem response (ABR) at ≤90 decibels (dB), achieving the trial’s key secondary endpoint.

Hearing improvements remained stable or continued to improve in 8 participants who had follow-up visits of ≥36 weeks (up to 72 weeks). Speech development was also assessed in the 3 participants who were followed at least 48 weeks and all showed significant improvements. One of these participants demonstrated the ability to identify one- and two-syllable words with no visual cues and could respond to distant sounds and speech in noisy environments.

Across all 12 participants, both the surgical procedure and DB-OTO were well tolerated, and there were no DB-OTO-related adverse findings reported. Two participants experienced serious adverse events: one was attributed to a cochlear implant surgical complication and the other to a recent vaccination. Some participants experienced transient post-surgical vestibular adverse events (e.g., nystagmus, nausea, dizziness, vomiting), all of which fully resolved.

The U.S. regulatory application for DB-OTO is planned for later this year, pending discussions with the U.S. Food and Drug Administration (FDA). DB-OTO received Orphan Drug, Rare Pediatric Disease, Fast Track and Regenerative Medicine Advanced Therapy designations from the FDA. The European Medicines Agency also granted Orphan Drug Designation.

The potential use of DB-OTO for OTOF-related hearing loss is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority.

About OTOF-related Hearing Loss
Permanent congenital hearing loss (present at birth) is a significant unmet medical need that affects approximately 1.7 out of every 1,000 children born in the U.S. and approximately half of these cases have genetic causes. Notably, otoferlin-related hearing loss is ultra-rare, affecting 20-50 newborns per year in the U.S. This specific condition is caused by variants in the OTOF gene, which lead to a lack of a functional otoferlin protein that is critical for the communication between the sensory cells of the inner ear and the auditory nerve.

About the CHORD Trial
The CHORD trial is a registrational Phase 1/2 multicenter, open-label trial to evaluate the safety, tolerability and efficacy of DB-OTO in infants, children and adolescents with OTOF-related hearing loss. The trial is currently enrolling children (<18 years of age) across sites in the U.S., United Kingdom, Spain and Germany.

CHORD is being conducted in two parts. In the initial dose-escalation cohort (Part A), participants receive a single intracochlear infusion of DB-OTO in one ear. In the expansion cohort (Part B), participants receive DB-OTO in both ears at the selected dose from Part A.

Hearing improvements were assessed by PTA and ABR. PTA is the gold standard measurement of hearing sensitivity and is measured through behavioral responses to sound (e.g., turning head towards sound) that is emitted at different intensity levels and measured in dB. ABR corroborates these behavioral responses, serving as an objective confirmation of hearing function, and is measured through recording electrical brainstem responses to sound emitted at different intensity levels measured in dBs. At baseline, all participants had profound hearing loss (behavioral PTA), and no electrophysiological (ABR) responses at maximum sound levels.

Additional information about the trial, including enrollment, can be obtained by contacting [email protected].

About DB-OTO and the Regeneron Auditory Program
DB-OTO is an investigational cell-selective, dual adeno-associated virus (AAV) vector gene therapy designed to provide durable, physiological hearing to individuals with profound, congenital hearing loss caused by variants of the OTOF gene. The treatment aims to deliver a working copy of the OTOF gene to replace the non-functional otoferlin protein using a modified, non-pathogenic virus that is delivered via an infusion into the cochlea under general anesthesia (similar to the procedure used for cochlear implantation). In this gene therapy, the newly introduced OTOF gene is under the control of a proprietary cell-specific Myo15 promoter, which is intended to restrict expression only to hair cells that normally express otoferlin.

In addition to OTOF, Regeneron is committed to investigating several other targets for genetic forms of hearing loss.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit, www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation the investigational gene therapy DB-OTO; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products, such as DB-OTO for the treatment of otoferlin-related hearing loss; uncertainty of the utilization, market acceptance, and commercial success of Regeneron’s Products and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron’s Products and Regeneron’s Product Candidates (such as DB-OTO); the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products and Regeneron’s Product Candidates (such as DB-OTO) in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes in laws, regulations, and policies affecting the healthcare industry; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates (including biosimilar versions of Regeneron’s Products); the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2024 and its Form 10-Q for the quarterly period ended June 30, 2025. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).

Analyst’s Disclosure:I/we have a beneficial long position in the shares of JPM.PR.M either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I may add additional preferred shares to my portfolio, but I haven't decided yet which ones. I have sold my entire position in JPMorgan

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Plus. the “cobot” revolution, Musk's xAI supercomputer bonanza and how AI is complicating career advice, in this edition of the Technology newsletter.

Detainees are made to stand against a bus before being handcuffed, during a raid by federal agents where about 300 South Koreans were among 475 people arrested at the site of a $4.3 billion project by Hyundai Motor and LG Energy Solution to build batteries for electric cars in Ellabell, Georgia, U.S., September 4, 2025 in a still... Purchase Licensing Rights, opens new tab Read more

CompaniesOct 12 (Reuters) - Three workers have died since Hyundai Motor

(005380.KS), opens new tab started construction of its $7.6 billion auto plant in Georgia in 2022, the Wall Street Journal reported on Sunday, citing a review of federal records.

Dozens of the company's current and former workers, many of them safety coordinators who helped oversee construction, told the newspaper in interviews that the work environment involved many inexperienced immigrant laborers, often lax safety standards and frequent accidents.

Sign up here.

The plant, which is operated through a joint venture between Hyundai and South Korea's LG Energy Solution

(373220.KS), opens new tab, has been in the limelight since an immigration raid last month that detained hundreds of South Korean workers in the largest single-site enforcement operation in the U.S. Department of Homeland Security's history.

Apart from the deaths, more than a dozen workers have suffered serious injuries, including from falling without wearing harnesses and getting crushed by forklifts, according to the WSJ.

The workers interviewed by the WSJ said Hyundai did not ensure that people were properly trained, and safety regulators did little to prevent worksite violations, the report added.

Reuters could not immediately confirm the report. Hyundai did not immediately respond to a Reuters request for comment.

Hyundai said in a statement to the WSJ that it is committed to following immigration laws and that it doesn't compromise safety for the sake of speed, adding that the company took steps to address safety issues in response to incidents during construction.

"We acted immediately and comprehensively to prevent anything like this from happening again," Hyundai CEO Jose Munoz told the newspaper. "I traveled to Georgia to tell our team directly: Their safety comes before production schedules, before costs, before profits, before everything."

Construction on the electric vehicle and battery plant, located in Bryan County about 30 miles west of Savannah, is ongoing.

Reporting by Angela Christy in Bengaluru; Editing by Mark Porter

Our Standards: The Thomson Reuters Trust Principles., opens new tab

AI stocks are a massive opportunity, but picking individual winners isn't for everyone.

One of the best uses of index funds is to get exposure to areas of the stock market where you want to invest but may not be completely comfortable picking individual stocks yourself.

There's no doubt that artificial intelligence, or AI, is one of the most interesting and promising investment opportunities of our time. But picking individual winners can seem like an intimidating task.

One of the biggest problems is that artificial intelligence ETFs -- and there are a few -- tend to have relatively high investment fees. But there's a Vanguard ETF that can give you excellent AI exposure at a fraction of the cost of most other artificial intelligence ETFs -- the Vanguard Information Technology ETF (VGT -4.08%).

Image source: Getty Images.

About the Vanguard Information Technology ETF
Technically speaking, the Vanguard Information Technology ETF isn't an AI-specific investment vehicle. Instead, it is a sector index fund that tracks information technology, which is one of the 11 S&P sectors.

Having said that, the bulk of the companies in the portfolio are major AI players. Semiconductor manufacturers make up 31% of the fund, for example, and software companies make up another 36%. And if we look at the list of the fund's 10 largest holdings (which make up 58% of the assets), aside from maybe Apple (AAPL -3.40%), it reads like a "who's who" of the biggest AI winners in the market.

Company (Symbol)

% of Fund

Nvidia (NVDA -4.84%)

17.18%

Microsoft (MSFT -2.17%)

13.73%

Apple (AAPL -3.40%)

13.05%

Broadcom (AVGO -5.90%)

4.32%

Oracle (ORCL -1.33%)

2.02%

Palantir (PLTR -5.39%)

1.86%

Cisco (CSCO -2.85%)

1.50%

AMD (AMD -7.78%)

1.44%

Salesforce.com (CRM -1.31%)

1.32%

International Business Machines (IBM -3.54%)

1.23%

Data source: Vanguard. Holdings as of Aug. 31, 2025.

Like most Vanguard ETFs, the Vanguard Information Technology ETF is a low-cost investment product. It has a 0.09% expense ratio, which means that for every $1,000 in assets, you'll pay $0.90 in investment fees annually. To be sure, this isn't a fee that you actually have to pay, but it will be reflected in the fund's performance over time.

Here's why this is so important. The most popular AI-specific ETFs all have expense ratios that are much higher. For example, the Global X Artificial Intelligence and Technology ETF (AIQ -4.56%) has a 0.68% expense ratio. Over a long holding period, this difference in fees could literally mean thousands of dollars in additional returns.

To illustrate this, let's say that the stocks owned by both funds return an average of 12% per year for the next 20 years, and that you invest $10,000 in each of them. The fund with a 0.68% expense ratio would grow your money to about $85,400. The Vanguard fund with a 0.09% expense ratio would produce over $9,500 more.

A word of caution
It's also worth noting that that the reasons to buy the Vanguard Information Technology ETF are also the reasons to be cautious -- specifically when it comes to the concentration in the largest tech companies. Nearly 45% of the fund is concentrated in Nvidia, Microsoft, and Apple, so if any of those three has a bad earnings report or other negative news, it could have a big impact on the fund. Just keep this in mind before you invest.

The bottom line is that the Vanguard Information Technology ETF is an excellent way to get all-in-one exposure to the biggest and most successful names in AI with a bare minimum of investment fees. If you are looking for ways to benefit from the AI boom without choosing individual stocks on your own, this could be a great way to do it.

Matt Frankel has positions in Advanced Micro Devices. The Motley Fool has positions in and recommends Advanced Micro Devices, Apple, Cisco Systems, International Business Machines, Microsoft, Nvidia, Oracle, Palantir Technologies, and Salesforce. The Motley Fool recommends Broadcom and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.

Tesla (TSLA -4.97%) investors have waited years for a lower-cost model. Its CEO, Elon Musk, has referenced a $35,000 price point as crucial to success as long ago as 2013, and originally the Model 3 was sold for a little under $50,000 back in 2017.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The analysis is provided exclusively for informational purposes and should not be considered professional investment advice. Before investing, please conduct personal in-depth research and utmost due diligence, as there are many risks associated with the trade, including capital loss.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

CCM Investment Advisers disclosed a new position in Advanced Micro Devices (AMD -7.78%) in its October 10, 2025 Securities and Exchange Commission filing. The estimated $11.13 million purchase occurred in the third quarter of 2025.

What happenedAccording to a Securities and Exchange Commission filing dated October 10, 2025, CCM Investment Advisers established a new position in Advanced Micro Devices, purchasing 68,820 shares. The estimated transaction value was $11.13 million for the period ended September 30, 2025. The position represented 1.1% of the fund's $1.02 billion in reportable U.S. equity assets.

What else to knowCCM Investment Advisers' new AMD stake represents 1.1% of 13F assets, and is outside the fund's top five positions.

The company's top holdings after the filing as of September 30, 2025 are:

NASDAQ:NVDA: $40.55 million (4.0% of AUM)NASDAQ:AVGO: $36.12 million (3.6% of AUM)NASDAQ:GOOGL: $35.72 million (3.5% of AUM)NASDAQ:MSFT: $33.70 million (3.3% of AUM)NASDAQ:AAPL: $32.84 million (3.2% of AUM)As of October 9, 2025, AMD shares were priced at $232.89, up 36.18% over the prior 12 months, outperforming the S&P 500 by 17.67 percentage points over the past year.

Advanced Micro Devices reported $29.6 billion in trailing 12-month revenue, and $2.8 billion in net income for the trailing 12 months ending June 28, 2025.

The company’s forward price-to-earnings ratio is 28.57, and its enterprise value to EBITDA multiple is 48.83 as of October 10, 2025.

Company OverviewMetricValueRevenue (TTM)$29.60 billionNet Income (TTM)$2.83 billionPrice (as of market close 2025-10-09)$232.89One-Year Price Change36.18%Company SnapshotAdvanced Micro Devices, Inc. (AMD) is a leading global semiconductor company specializing in high-performance computing and graphics solutions. The company’s strategy centers on innovation in CPUs, GPUs, and data center technology, targeting growth in the enterprise, cloud, and gaming sectors. AMD's competitive edge is driven by its advanced product portfolio and strong relationships with major technology partners worldwide.

The company produces x86 microprocessors, discrete and integrated GPUs, server and embedded processors, and semi-custom system-on-chip (SoC) products for computing, graphics, data center, and gaming applications.

IMAGE SOURCE: AMD.

AMD generates revenue primarily from the sale of processors and graphics products to OEMs, cloud service providers, system integrators, and independent distributors. It serves original equipment manufacturers, cloud service providers, system integrators, and online retailers in the global computing, data center, artificial intelligence, and gaming markets.

Foolish takeFor CCM Investment Advisers to begin investing in AMD at this time is noteworthy because stocks in the artificial intelligence sector have been hot for some time now. Moreover, CCM already held shares in AI chip leader Nvidia, so why did it jump into AMD now?

The AI market went into overdrive in the third quarter of 2025 after Nvidia announced blockbuster deals with Intel and OpenAI. The British government also partnered with OpenAI in the quarter to expand AI infrastructure capacity in the country.

A rising tide lifts all boats, as the saying goes, so CCM could be anticipating AMD's growth amidst this environment. In fact, AMD announced its own partnership with OpenAI on Oct. 6. The partnership involves the semiconductor giant providing a massive number of its products to the ChatGPT creator, and is projected to deliver billions of dollars in revenue to AMD over the coming years.

As a result, AMD shares soared to an all-time high exceeding $240 on Oct. 9. While the company is a good investment and the stock has pulled back from its record high, it's worth waiting to see if the share price retreats further before deciding to buy.

Glossary13F assets: The value of U.S. equity securities reported by institutional investment managers in quarterly SEC Form 13F filings.
Stake: The amount of ownership or shares an investor or fund holds in a particular company.
Top holdings: The largest investments by value within a fund's portfolio.
AUM (Assets Under Management): The total market value of assets a fund or investment manager oversees on behalf of clients.
Outperforming: Achieving a higher return compared to a benchmark index or peer group over a specific period.
Trailing twelve months (TTM): The 12-month period ending with the most recent quarterly report.
Forward price-to-earnings ratio: A valuation metric comparing a company's current share price to its projected future earnings per share.
Enterprise value to EBITDA multiple: A valuation ratio comparing a company's total value to its earnings before interest, taxes, depreciation, and amortization.
System-on-Chip (SoC): An integrated circuit that combines multiple components, such as CPU, GPU, and memory, onto a single chip.
Original equipment manufacturers (OEMs): Companies that produce parts or equipment used in another company's end products.
Cloud service providers: Companies offering computing resources, storage, or services over the internet to businesses or individuals.
Data center: A facility housing computer systems and associated components for storing, processing, and managing large amounts of data.

Robert Izquierdo has positions in Advanced Micro Devices, Alphabet, Apple, Broadcom, Intel, Microsoft, and Nvidia. The Motley Fool has positions in and recommends Advanced Micro Devices, Alphabet, Apple, Intel, Microsoft, and Nvidia. The Motley Fool recommends Broadcom and recommends the following options: long January 2026 $395 calls on Microsoft, short January 2026 $405 calls on Microsoft, and short November 2025 $21 puts on Intel. The Motley Fool has a disclosure policy.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in ZETA over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Stocks are approaching a clear test after investors were left in the fog of a government shutdown this month and rattled by fresh tariff fears Friday.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of BRK.B either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Bohdan Kucheriavyi is not a financial/investment advisor, broker, or dealer. He's solely sharing personal experience and opinion; therefore, all strategies, tips, suggestions, and recommendations shared are solely for informational purposes. There are risks associated with investing in securities. Investing in stocks, bonds, options, exchange-traded funds, mutual funds, and money market funds involves the risk of loss. Loss of principal is possible. Some high-risk investments may use leverage, which will accentuate gains & losses. Foreign investing involves special risks, including greater volatility and political, economic, and currency risks and differences in accounting methods. A security’s or a firm’s past investment performance is not a guarantee or predictor of future investment performance.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against C3.ai, Inc. (“C3.ai” or “the Company”) (NYSE: AI) and certain of its officers.

Class Definition

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired C3.ai securities between February 26, 2025 and August 8, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/AI.

Case Details

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) the health of C3.ai’s Chief Executive Officer was materially impairing the Company’s ability to close deals; (2) management was unable or otherwise ineffectual in mitigating the impact of the CEO’s health on business operations; and (3) as a result, C3.ai’s ability to execute on its profit and growth potential was significantly compromised.

What's Next?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/AI. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in C3.ai you have until October 21, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]

NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Nutex Health Inc. (“Nutex” or “the Company”) (NASDAQ: NUTX) and certain of its officers.

Class Definition

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Nutex securities between August 8, 2024 and August 14, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/NUTX.

Case Details

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) HaloMD was generating lucrative arbitration outcomes for Nutex by engaging in a coordinated scheme to defraud insurance companies; (2) revenues derived from Nutex’s engagement with HaloMD in the IDR process were unsustainable to the extent they resulted from fraudulent conduct; (3) the Company overstated both the extent to which it had remediated, and its ability to remediate, material weaknesses in its internal controls over financial reporting; (4) as a result, Nutex was unable to account for the treatment of certain stock-based compensation obligations effectively; (5) Nutex improperly classified these stock-based compensation obligations as equity rather than liabilities;
(6) the foregoing increased the risk that Nutex would be unable to timely file certain financial reports with the United States Securities and Exchange Commission (“SEC”); (7) accordingly, Nutex’s business and financial prospects were overstated; and (8) as a result, Defendants’ public statements about the Company’s business, operations, and prospects were materially false and misleading at all relevant times.

What's Next?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/NUTX. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Nutex you have until October 21, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]

Sun, 12/10/2025 - 13:11

Peter Brandt, trading veteran, turns bullish on Bitcoin, XRP, Ethereum and Stellar after $16 billion liquidation bloodbath

Cover image via U.Today

Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

Crypto just survived one of the hardest weeks in four years. U.S. tariffs on Chinese exports pushed Bitcoin all the way down to $100,600 before it recovered above $111,000.

More than $16 billion in liquidations hit derivatives, leaving traders unsure if the cycle was broken. Into this setup, Peter Brandt posted charts for four majors — and all of them came out bullish in his opinion.

XRP is at $2.46. Brandt said the recent pullback is "a minor reaction." The breakout from last year’s wedge is still valid, with $1.79 acting as support and $3.00-$3.50 standing as the next targets.

HOT Stories

A few final posts for the weekend, then I will leave you youngsters with your dreams$XRP - just a minor reaction in bigger theme of things$BTC - bull still alive and well$XLM - a bull waking from a nap$ETH - ready to rock and roll
If I change my mind I won't let you know pic.twitter.com/rL1nVETYSn

— Peter Brandt (@PeterLBrandt) October 11, 2025 Bitcoin closed the week at $112,011. His verdict: "Bull still alive and well." The line that matters runs through $109,000-$110,000. Above, the SMA at $113,897 and resistance between $123,000-$126,000 are the next points to watch.

Stellar (XLM) and Ethereum in focusStellar trades at $0.33. Brandt called it "a bull waking from a nap." The key level is $0.25 on the downside, while $0.60 remains the resistance wall that could open up a much bigger move.

Ethereum is at $3,813 and "ready to rock and roll," according to the trader. Support sits at $3,072, resistance up at $4,700-$4,800. A break above would clear the long consolidation that has capped ETH since 2021.

The wider market is still heavy after the tariff shock, but Brandt’s message is simple: The main structures on XRP, BTC, XLM and ETH are unbroken, and the bigger trade is still pointing up.

Related articles

ZEC is up 74% weekly, staying resilient while most altcoins fell during the crypto crash.Both retail and institutional buying continue, with MFI above 95 and CMF near 0.25.The rally could extend to $331 and beyond if support at $251 holds, but overleveraged longs may trigger volatility.While most altcoins are still trying to recover from the recent crypto market crash, the Zcash (ZEC) price seems to be living in a different world. The privacy-focused token has climbed nearly 74% in the past week, holding firm while others wobbled.

What’s driving this strength isn’t hype — it’s conviction. Both large holders and retail traders are quietly buying the dips, and ZEC’s price chart shows that momentum could still have some room left. But with more upside comes a few risks, too.

Sponsored

Buyers Refuse to Back Down as Money Keeps Flowing InZcash’s buying pressure has held steady even through the market-wide panic. Both institutional and retail activity have stayed strong, the two segments that usually move in opposite directions during crashes.

The Money Flow Index (MFI), which tracks buying strength and trading volume, sits above 95, showing that traders are still actively buying at higher prices.

Meanwhile, the Chaikin Money Flow (CMF), which reflects larger or institutional activity, remains positive around 0.25, confirming that big players haven’t stepped away.

Zcash Money Flow: TradingViewWant more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter here.

Sponsored

Together, these trends explain why the ZEC price rebounded so sharply after briefly dipping to $150 on October 10 (threatened by the crash).

Buyers quickly absorbed the fall, sending the ZEC price back to nearly $290. This consistent inflow of money — from both retail and whales — has kept Zcash’s uptrend intact even when most of the market turned red.

However, CMF hasn’t yet climbed back to its early-October peak. That means while buying is strong, full-scale institutional momentum hasn’t fully returned. If large money picks up again, the Zcash price rally could easily stretch further.

Sponsored

Leverage Traders Could Be the SpoilerThe only major risk for the Zcash price right now lies in the derivatives market. Data from Bybit’s ZEC/USDT liquidation map shows that the market is heavily tilted toward long positions — $21.49 million in cumulative long leverage versus just $3.43 million in shorts.

Zcash Longs Can Pose A Risk: CoinglassThat means most traders are betting on ZEC’s price to keep rising. But if the price drops suddenly toward $178, all those leveraged longs could start getting liquidated, creating a chain reaction of forced selling — similar to what triggered the recent broader crash.

So while spot buying remains strong, leverage traders might be building a pressure point that could spark short-term volatility if sentiment shifts.

Sponsored

Can Zcash Hold Its Ground Above $250?Zcash’s daily chart shows that the rally is still technically sound. The token continues to trade inside an ascending triangle, with Fibonacci levels providing strong structure. At press time, ZEC sits around $287, with immediate support near $251.

Zcash Price Analysis: TradingViewIf the price manages to hold that level — and if buying pressure continues from both retail and whales — ZEC could move toward $331, which is the next resistance to beat. A daily close above that would likely open the door to $461, continuing the strong run.

But if leveraged positions start to unwind, the first fallback zones sit around $223 and $170. Those would be key areas for dip buyers to step in again if the rally cools off.

Disclaimer

In line with the Trust Project guidelines, this price analysis article is for informational purposes only and should not be considered financial or investment advice. BeInCrypto is committed to accurate, unbiased reporting, but market conditions are subject to change without notice. Always conduct your own research and consult with a professional before making any financial decisions. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

Cover image via U.Today

Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

The last day of the week is mainly bearish for the market, according to CoinMarketCap.

Top coins by CoinMarketCapSHIB/USDThe rate of SHIB has declined by 3.78% over the last 24 hours.

Image by TradingViewOn the hourly chart, the price of SHIB has made a false breakout of the local resistance of $0.00001011. However, if the daily bar closes near that mark, one can expect an upward move to the $0.00001030 range.

Image by TradingViewOn the bigger time frame, the rate of the meme coin is within yesterday's candle. The volume is declining after the dump a few days ago.

You Might Also Like

Neither buyers nor sellers have accumulated enough energy to seize the initiative. All in all, traders are unlikely to witness sharp ups or downs shortly.

Image by TradingViewFrom the midterm point of view, the price of SHIB has made a false breakout of the $0.00000832 support. At the moment, one should focus on the $0.00001145 level. While the rate is below that mark, bears keep controlling the situation on the market.

SHIB is trading at $0.00001003 at press time.

Journalist

Posted: October 12, 2025

Key Takeaways
Why did Hyperliquid record massive liquidations? 
Most positions were forcefully closed to ensure the platform remains debt-free.  

What’s next post-market crash? 
Leaders are calling for better use of insurance funds to safeguard traders’ capital. 

Hyperliquid [HYPE] faced massive criticism following its massive liquidation during the recent crash. It topped the charts with $10 billion worth of positions wiped out. 

In response, Kris Marszalek, CEO of the exchange Crypto.com, called for a probe into Hyperliquid and other top platforms. 

“Regulators should look into the exchanges that had most liquidations in the last 24h and conduct a thorough review of fairness of practices.”

Source: X

Hyperliquid slams criticism
However, Jeff Yan, CEO and Co-Founder of Hyperliquid, said the claims were “irresponsible.” He clarified that DEX’s liquidation was the highest because it was the most transparent and shared full data. 

Most CEXs only allow CoinGlass to sample a limited amount of liquidation data.

In fact, some estimated that the overall liquidation could be as high as $40 billion. That’s double the reported amount of about $20 billion. 

Yan added that the move was per the Hyperliquid standard procedures to ensure there is no “irresponsible gambling” and bad debt. 

“Any system that does not liquidate the necessary users is irresponsibly gambling with other users’ funds. On Hyperliquid, every order, trade, and liquidation is transparently verifiable on-chain.”

Source: X

Yan said Hyperliquid didn’t target profitable positions and used auto-liquidation to maintain the platform’s solvency.

“Contrary to misconceptions, HLP is a non-toxic liquidator that does not pick profitable liquidations.”

For the unfamiliar, perpetual trading or leveraged positions are a zero-sum game by design. For every short, there should be a corresponding long.

In this setup, winning shorts earn profits funded by losses from leveraged longs.

But if one side is wiped out (bulls) and shorts make more money as the market crashes, there’s not enough money to pay the winning short sellers. Exchanges close even profitable short positions to prevent bad debt.

Auto-deleveraging (ADL) is the liquidation of last resort. Yan said exchanges apply ADL when their insurance funds or vaults fail to absorb the crash.

Most platforms opted for it during the crash, capping gains and even wiping out other traders’ capital. 

Calls for better risk tools
For his part, Tushar Jain, Partner at Multicoin Capital, urged exchanges to use insurance funds to avoid such “value destruction” for users. 

Source: X

That said, the market slipped into an “extreme fear” level seen during the “Liberation Day” tariffs in April.

Historically, this has always been a buying signal. But only a positive update on the China-U.S. tariff wars could calm and juice the markets again. 

XRP tumbled to under $1 on some exchanges.

While bitcoin and ether crashed by up to 30% during the market-wide meltdown on Friday evening and Saturday morning, XRP, which is among the largest altcoins, suffered a substantially more painful decline that saw it dump well below $1.5 on most exchanges and even beneath $1 on Binance.

In the span of just 30 minutes, the asset’s market capitalization experienced a 50% dump that pushed the metric to $80 billion by 5:20 PM ET. It was at $161 billion at 4:50 PM ET, according to the Kobeissi Letter.

This was an unprecedented liquidation event:

Amid the crypto crash yesterday, $XRP erased a whopping -50% of its market cap in 30 MINUTES.

At 4:50 PM ET, $XRP was worth $161 billion.

By 5:20 PM ET, $XRP was worth $80 billion.

What happened to XRP? https://t.co/oACmCgYpc2 pic.twitter.com/fUC9U0zeI2

— The Kobeissi Letter (@KobeissiLetter) October 11, 2025

What Happened to XRP?
It’s worth noting that the $0.80 price tag on Binance meant that Ripple’s cross-border token had tanked to its lowest levels in a year when its rally began after the US presidential elections. However, there’s a significant discrepancy between XRP’s bottom on Binance and other exchanges, as the asset remained above $1.20 on most of the competition.

Naturally, this has raised a few eyebrows in the cryptocurrency community, especially within the ever-vocal XRP Army.

ERGAG CRYPTO, for once, believes this crash was “designed to liquidate all XRP long positions.” The analyst went further, blaming Binance and its former CEO for the collapse, while highlighting the difference in price drops among the largest digital assets.

“The market collapsed in just 8 minutes, and #XRP experienced the highest percentage drop compared to #BTC and #ETH. #BTC only dropped 13% from $118K, which was a normal retracement. #ETH fell by 14-15%. That’s unusual! and #XRP from $2.65 dropped 70%.”

What’s Next for XRP?
Now that the dust has settled, XRP has recovered a lot of ground from the recent lows and is up to $2.40 on all exchanges. However, popular crypto analyst Ali Martinez indicated that the asset might not be out of the woods yet.

You may also like:

Altcoin Bloodbath: ETH, XRP, SOL, DOGE Crumble as Liquidations Near $900M

XRP Whales Offload $50M Daily: Sell Pressure Threatens Price Drop

Why Ripple’s (XRP) $3 Support Could Be the Start of a New Rally

He posted a chart showing whether XRP’s current price is above a critical red line, which would mean a more bullish outlook. Yet, the asset’s recent correction has pushed it below that line, which he categorized as “bearish” news for Ripple’s token.

$XRP:

– Below the red line = bearish.

– Above the red line = bullish. pic.twitter.com/SHtWLEHIPF

— Ali (@ali_charts) October 12, 2025

Bitcoin steadies near $111K as ARK Invest sees record ETF inflows, 30% supply density, and easing inflation — BTC price prediction eyes $126K breakout.

Pi Coin held the $0.15 support despite a 23% weekly drop during the broader crypto crash.Shrinking sell volume and steady money flow suggest early accumulation by larger holders.A breakout above $0.205 could open an 18–44% upside range, with $0.238, $0.264, and $0.290 as targets.The market crash triggered by renewed US–China tariff tensions sent most altcoins sharply lower. Yet Pi Coin (PI) held its ground better than expected. Despite losing nearly 23% over the past week (part of it happening during the crash), the Pi Coin price managed to stay above the $0.15 support, showing resilience at a time when most tokens broke lower.

Since October 7, Pi has steadily recovered and now trades close to $0.20, hinting that buyer confidence may be quietly returning. A closer look at both the chart and on-chain behavior suggests that Pi could be gearing up for a rebound, provided selling pressure keeps cooling off.

Sponsored

Shrinking Sell Volume and Money Flow Show Buyers Are ReturningOn the daily chart, the volume spread pattern—often studied in Wyckoff-style analysis—helps identify shifts in buying and selling strength.

During the tariff-driven crash, a red bar dominated the chart, signaling full control by Pi Coin sellers. But that bar has now turned yellow, meaning sellers remain active but with less intensity.

Pi Coin Sell Pressure Shrinking: TradingViewWant more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter here.

More importantly, the yellow bars have been shrinking. That shows selling momentum is fading, and buyers are gradually stepping in.

Sponsored

The last time this shrinking pattern appeared was in early August, when Pi Coin rallied nearly 40% in just four days. If this trend continues without another spike in red sell bars, PI could see a similar short-term rebound again.

The Chaikin Money Flow (CMF)—which measures how much large-scale or institutional money is entering or leaving an asset—adds to this positive setup.

Even though CMF briefly dipped below zero, it remains well above its October 7 low and far stronger than its late-August levels.

Pi Coin CMF: TradingViewSponsored

This means big traders are still quietly accumulating Pi Coin, even as smaller investors remain cautious (exhibited by still-yellow Wyckoff bars). Together, these signals reflect a cooling sell-off and slow return of buyer strength.

Bullish Divergence Hints at a Pi Coin Price Reversal in MotionOn the 12-hour chart, Pi Coin’s price has formed a bullish RSI divergence between September 23 and October 10. While the price made a lower low, the Relative Strength Index (RSI) made a higher low, showing that downward momentum is losing force.

While this kind of divergence is usually associated with trend reversals, considering PI’s weak price history, a rebound looks more likely.

Sponsored

(RSI measures momentum between 0 and 100, showing when an asset is overbought or oversold.)

At the time of writing, PI trades at $0.201, sitting near the 0.236 Fibonacci retracement level. A 12-hour candle close above $0.205 could confirm a breakout attempt toward the next resistance at $0.238 — a roughly 18% upside from the current price.

Pi Coin Price Analysis: TradingViewIf that move holds, PI could stretch gains toward $0.264 (about 31% higher) and possibly $0.290 (around 44% above current levels).

However, a drop below $0.184 would invalidate this rebound setup and could push the Pi Coin price back toward even $0.153, depending on how the broader market reacts.

Disclaimer

In line with the Trust Project guidelines, this price analysis article is for informational purposes only and should not be considered financial or investment advice. BeInCrypto is committed to accurate, unbiased reporting, but market conditions are subject to change without notice. Always conduct your own research and consult with a professional before making any financial decisions. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

Cover image via U.Today

Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

Some coins have returned to the green zone, while the prices of others keep falling, according to CoinStats.

SOL chart by CoinStatsSOL/USDThe rate of Solana (SOL) has remained the same since yesterday. Over the last week, the price has fallen by 21%.

Image by TradingViewOn the hourly chart, the price of SOL is about to break the local resistance of $182.97. If that happens, the upward move is likely to continue to the $190 mark.

Image by TradingViewOn the bigger time frame, neither side is dominating as the rate is far from the main levels. The volume is going down, confirming the absence of bulls' or bears' strength.

You Might Also Like

In this regard, sideways trading in the range of $175-$190 is the more likely scenario.

Image by TradingViewFrom the midterm point of view, sellers are more powerful than buyers. If the weekly candle closes around the current prices or below, the correction is likely to continue to the support of $157 the upcoming week.

SOL is trading at $183 at press time.

Crypto investors might be nursing some serious portfolio bruises this week, but bitcoin miners have their own headache — earnings per petahash just hit a five-month low, and it's not exactly the kind of milestone anyone's celebrating.

Cover image via U.Today

Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

The market is neutral on the last day of the week, according to CoinStats.

Top coins by CoinStatsBTC/USDThe rate of Bitcoin (BTC) has fallen by 0.44% since yesterday.

Image by TradingViewDespite today's fall, the price of BTC is looking bullish on the hourly chart. If a breakout of the local resistance of $112,213 happens, the growth is likely to continue to the $113,000 mark.

Image by TradingViewOn the bigger time frame, the rate of the main crypto has set a local support at $109,711. However, buyers might need more time to accumulate energy for a further move.

You Might Also Like

In this case, sideways trading in the narrow range of $111,000-$114,000 is the more likely scenario.

Image by TradingViewFrom the midterm point of view, the situation is bearish. If the weekly candle closes below the previous bar low ($111,597), there is a high probability to witness an ongoing correction to the $100,000-$105,000 area.

Bitcoin is trading at $111,773 at press time.

At 8 a.m., Bitcoin's value fluctuated between $111,760 and $112,091, reflecting a period of limited volatility despite widespread bearish indicators across various timeframes. The world's leading cryptocurrency boasts a market capitalization of $2.23 trillion, with a 24-hour trading volume reaching $68.04 billion.

Why Trust CoinGape

CoinGape has covered the cryptocurrency industry since 2017, aiming to provide informative insights to our readers. Our journal analysts bring years of experience in market analysis and blockchain technology to ensure factual accuracy and balanced reporting. By following our Editorial Policy, our writers verify every source, fact-check each story, rely on reputable sources, and attribute quotes and media correctly. We also follow a rigorous Review Methodology when evaluating exchanges and tools. From emerging blockchain projects and coin launches to industry events and technical developments, we cover all facets of the digital asset space with unwavering commitment to timely, relevant information.

Michael Saylor has sparked fresh speculation of another Bitcoin purchase following the sharp crypto market downturn on Friday. The MicroStrategy founder shared a chart of his company’s Bitcoin portfolio, now worth $71.7 billion, with the caption, “Don’t Stop ₿elievin’.”

MicroStrategy is Poised for Another Bitcoin Accumulation
Saylor’s post is a possible sign that MicroStrategy could add more Bitcoin to its already massive holdings. The chart revealed that MicroStrategy currently owns 640,031 BTC, purchased at an average price of $73,983 per coin.

Don’t Stop ₿elievin’ pic.twitter.com/LUMroqLSCl

— Michael Saylor (@saylor) October 12, 2025

The overall worth of the company holdings has increased by over 51% since the initial purchase. This indicates profits of more than $24 billion. All orange dots on the graph symbolize a Bitcoin buy moment. This demonstrates that Saylor’s firm continues to buy BTC during market rallies and falls.

His latest post came as BTC price stabilized above $110,000. This follows the steep selloff that rattled altcoins and erased billions from the broader crypto market on October 10. The firm has long been known for its conviction-based accumulation model. It uses Bitcoin as a corporate treasury reserve asset rather than a short-term investment.

Tether Reaffirms Commitment to Bitcoin and Gold Investments
Meanwhile, the market received another bullish statement from Paolo Ardoino, the CEO of Tether. Responding to a quote of his earlier comments, Ardoino wrote, “Bitcoin and Gold will outlast any other currency.”

His post reaffirms Tether’s stance on allocating profits toward assets viewed as a long-term store of value. The Tether CEO added that the company will continue to invest in Bitcoin and Gold.

This implies that the company still focuses on safety and diversification in the face of increasing uncertainty in global financial markets. A similar perspective was recently shared by macro investor Raoul Pal. Pal noted that global liquidity trends remain supportive of Bitcoin and other risk assets despite recent selloffs.

Ardoino’s statement echoed Saylor’s philosophy that Bitcoin functions as “digital gold” in an era of unstable monetary policy and currency debasement.

Meanwhile, the Bitcoin dominance level has gotten stronger. BTC dominance has passed the 60.6% resistance point, per TradingView data. This is the first time it has done so in months.

It is an indication that capital is being shifted out of altcoins and into Bitcoin. Analyst CryptoPulse stated that a retest to about 62% may be a confirmation of a BTC-led recovery phase.

📊 BTC Dominance Breaks Key Level

After months of decline, Bitcoin Dominance has finally broken above its last swing high at ~60.6%, marking a clear shift in market structure. ⚡

This move signals capital rotation back into BTC as traders seek safety amid recent volatility.… pic.twitter.com/C6kVDInYpn

— CryptoPulse (@CryptoPulse_CRU) October 12, 2025

Investment disclaimer: The content reflects the author’s personal views and current market conditions. Please conduct your own research before investing in cryptocurrencies, as neither the author nor the publication is responsible for any financial losses.

Ad Disclosure: This site may feature sponsored content and affiliate links. All advertisements are clearly labeled, and ad partners have no influence over our editorial content.